The FDA extended the duration of use of Nexplanon for pregnancy prevention in women of reproductive potential for up to 5 years.
HSE data shows that, excluding general appointments, costs came to €31,396,464 last year. This included costs for contraceptive items of €16,472,479 ...
The U.S. Food and Drug Administration (FDA) has approved a label expansion for Nexplanon to allow its manufacturer, Organon (OGN), to market the birth control implant, indicating an efficacy duration ...
Abstract: Introduction: Vestibular implants targeting the semi-circular canals might offer a potential treatment approach for vestibulopathy patients. Electrical stimulation is provided to all three ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results